- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00275964
Development of Active Safety Surveillance System for Traditional Chinese Medicine
Context:Clinical trials demonstrating increased risk of cardiovascular disease and breast cancer among women randomized to hormone replacement therapy have attracted people's focus on the alternative therapy for menopausal symptoms. This study drug- a mixture of CHIA-WEI-HSIAO-YAO-SAN, CHIH-PO-TI-HUANG-WAN, HSIANG-SHA-LIU-CHUN-TZU-TANG (TMN1) is widely used as an alternative to hormonal therapies for hot flush in Taiwan. However, there is a paucity of data supporting their efficacy and safety.
Objective:To evaluate the safety and efficacy of TMN1 in the treatment of hot flush.
Design and Setting:A multi-center, prospective, observational follow-up study was conducted from July 2003 to December 2004 in 4 hospitals.
Participants:In total, 136 eligible subjects entered this study. They were required to take study drug 3 times a day for 12 weeks and make 9 visits at scheduled time for follow up efficacy and safety evaluations.
Main Outcome Measures:During the observation period, the investigators and study nurses actively enquired subjects if there was any adverse event (AEs) occurring to them by using Traditional Chinese medicine Adverse Events (TCM AE) questionnaire which includes 20 AEs proposed by experienced CM doctors as most commonly seen in the use of study drug. Every subject's complaint or abnormal laboratory value were carefully examined for possible causality and reviewed and decided by the research team. The primary outcome measure was the mean changes from baseline to week 12 in terms of frequency of hot flush and the severity of menopausal symptoms measured by the Kupperman Menopause Index. The secondary outcome measures included changes in quality of life measured by World Health Organization Quality of Life (WHOQOL) questionnaire, and adverse events monitored actively by a global assessment of tolerability. During the study period, every subject also received tests on routine hematology, biochemical function, and gynecologically relevant hormones at baseline visit, 4 weeks and 12 weeks after medication.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women between age of 45 and 55 and suffered from hot flushes and/or sweats
- had not participated in any trial within the previous 3 months before beginning this study
- were willing to participate in the trial and give written informed consent
Exclusion Criteria:
- had received any form of hormonal therapy within 3 months prior to the study
- had been diagnosed with any form of cancer and under treatment
- were afflicted with abnormal uterine bleeding and unknown etiology
- had hypertension or diabetes mellitus and were under treatment for these conditions
- had any abnormal finding for kidney, liver, or thyroid functions
- were currently taking antidepressants, alpha or beta-blocking agent, e.g., clomidine, ergot, ergot derivatives, or anti-estrogen medications such as tamoxifen and/or herbal hormones (isoflavon
- were suffering from arrhythmia or any other form of heart disease.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Jung Der Wang, M.D., Sc.D.,, Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 920807
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Climacteric Symptoms
-
Shandong Luye Pharmaceutical Co., Ltd.Unknown
-
Coordinación de Investigación en Salud, MexicoCompleted
-
Ache Laboratorios Farmaceuticos S.A.Withdrawn
-
Inna I. KovalenkoCompletedClimacteric SyndromeRussian Federation
-
Science Valley Research InstituteBiós FarmacêuticaRecruitingMenopause | Hypoestrogenism | Climacteric SyndromeBrazil
-
I.M. Sechenov First Moscow State Medical UniversityCompletedPerimenopause, Climacteric SyndromeRussian Federation
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause | Climacteric SyndromeRussian Federation
-
GlaxoSmithKlineCompletedMenopausal and Female Climacteric StatesUnited States, Australia, Argentina, Germany, United Kingdom, Spain, Italy, New Zealand, Sweden
Clinical Trials on TMN-1
-
Aurelia HospitalNot yet recruitingCoronary Microvascular Dysfunction | Resistant Hypertension | Hypertensive Heart Disease
-
University of Sao Paulo General HospitalCompleted
-
Orasis Pharmaceuticals Ltd.Completed
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
University of ThessalyCompleted
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department... and other collaboratorsCompleted
-
Yonsei UniversityCompletedObese Patients, One Lung VentilationKorea, Republic of
-
Queen Margaret UniversityNHS LothianTerminated